Why Is Repare Therapeutics Stock Trading Lower On Friday?

Core Insights - Repare Therapeutics Inc has released data from its MYTHIC Phase 1 trial evaluating the combination therapy of lunresertib and camonsertib for endometrial cancer and platinum-resistant ovarian cancer [1] Group 1: Clinical Findings - In the gynecologic cancer expansion cohort, 51 evaluable patients were enrolled as of the data cut-off date of November 14 [1] - For endometrial cancer, the overall response rate was 25.9%, with clinical benefit observed in 48.1% of patients, and a 24-week progression-free survival (PFS) rate of 43% [4] - In platinum-resistant ovarian cancer, the overall response rate was 37.5%, with clinical benefit in 79% of patients, and a 24-week PFS rate of 45% [5] Group 2: Safety Profile - Lunre+Camo therapy demonstrated a favorable tolerability profile compared to current and emerging therapies, with the most common adverse event being anemia at 26.9% (Grade 3) [2][3] Group 3: Regulatory and Development Plans - Repare has consulted with the FDA and the European Medicines Agency regarding registrational development plans for Lunre+Camo in gynecologic tumors [5] - The company plans to submit final Phase 3 trial protocols for regulatory clearance soon and aims to start the first Phase 3 trial in endometrial cancer in the second half of 2025 [6] Group 4: Market Reaction - Following the announcement, RPTX stock experienced a decline of 52.4%, trading at $1.89 [7]